Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

NCT06343064 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: Vebreltinib
DRUG: PLB1004

Sponsor

Avistone Biotechnology Co., Ltd.